

Adherium Consolidates Funding into A\$4.67 Million Term Loan

Melbourne, Australia – 16 September 2026: Adherium Limited (ASX:ADR) (“Adherium” or “the Company”), a global leader in digital respiratory management and developer of the US FDA-cleared Hailie® Smartinhaler® has obtained additional funding of AUD\$1.3 million from its major shareholder, Trudell Medical Limited (“Trudell”), a global leader in aerosol drug delivery and lung health devices from the management of respiratory conditions. Trudell has agreed to combine the current loan of AUD\$1,300,000 with previous short term unsecured loans in the amount of USD\$1,650,000 entered into on 29 June 2026 and AUD\$1,000,000 entered into on 14 August 2026 together with accrued interest into a term loan (“Term Loan”) due 31 August 2027 in the amount of AUD\$4,671,025. The Loan Facility will provide funding for working capital requirements.

Details of Loan Facility

The material terms of the Loan Facility are:

Loan facility	The principal amount is AUD\$4,671,025.
Interest	Interest will be charged on the principal amount at 12% per annum with interest capitalised monthly until repayment.
Repayment	The loan repayment date is 31 August 2027. Adherium may repay the Loan Facility at any time prior to the repayment date without penalty. The Loan Facility will become immediately repayable where there is an event of default.
Security	The Term Loan is unsecured.

Consideration of the Board

The Company has chosen to obtain the Term Loan from Trudell, rather than from an unrelated party, because alternative funding options (such as from third-party financiers), are limited, uncertain, or available only on terms that are materially less favourable to the Company on the basis that:

- the Term Loan does not dilute existing shareholders;

- the interest rate is considered to be reasonable in the circumstances;
- the ability to quickly execute the Term Loan as opposed to alternative funding options; and
- the funding available from Trudell is able to meet immediate working capital requirements.

The Board (with Mr George Baran who is associated with Trudell, abstaining) considers that the terms of the Loan Facility have been negotiated on arm's length terms, being on comparable terms to similar short term loans with unrelated parties, and therefore does not require shareholder approval under Part 2.E of the *Corporations Act 2001* (Cth).

Learn more at **adherium.com**

This ASX announcement was approved and authorised for release by the Board of Adherium.

- ENDS -

Investor Enquiries

Adherium Limited
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK Director
haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at **adherium.com**